Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

Smolen, J, Schoels, M, Nishimoto, N, Breedveld, F, Burmester, G, Dougados, M, Emery, P, Ferraccioli, G, Gabay, C, Gibofsky, A, Gomez-Reino, J, Jones, Graeme, Kvien, T, Murakami, M, Betteridge, N, Bingham, C, Bykerk, V, Choy, Ernest, Combe, B, Cutolo, M, Graninger, W, Lanas, A, Martin-Mola, E, Montecucco, C, Ostergaard, M, Pavelka, K, Rubbert-Roth, A, Sattar, N, Scholte-Voshaar, M, Tanaka, Y, Trauner, M, Valentini, G, Winthrop, K, de Wit, M and van der Heijde, D 2013. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Annals of the Rheumatic Diseases 72 (4) , pp. 482-492. 10.1136/annrheumdis-2012-202469

[img]
Preview
PDF - Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (253kB) | Preview

Abstract

Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), interleukin 6 (IL-6) pathway inhibition was evaluated in trials of TCZ and other agents targeting the IL-6 receptor and ligand in various RA populations and other inflammatory diseases. This consensus document informs on interference with the IL-6 pathway based on evidence and expert opinion. Methods: Preparation of this document involved international experts in RA treatment and RA patients. A systematic literature search was performed that focused on TCZ and other IL6-pathway inhibitors in RA and other diseases. Subsequently, incorporating available published evidence and expert opinion, the steering committee and a broader expert committee (both including RA patients) formulated the current consensus statement. Results: The consensus statement covers use of TCZ as combination- or monotherapy in various RA populations and includes clinical, functional and structural aspects. The statement also addresses the second approved indication in Europe JIA and non-approved indications. Also early phase trials involving additional agents that target the IL-6 receptor or IL-6 were evaluated. Safety concerns, including haematological, hepatic and metabolic issues as well as infections, are addressed likewise. Conclusions: The consensus statement identifies points to consider when using TCZ, regarding indications, contraindications, screening, dose, comedication, response evaluation and safety. The document is aimed at supporting clinicians and informing patients, administrators and payers on opportunities and limitations of IL-6 pathway inhibition.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
Uncontrolled Keywords: Interleukin-6 Receptors;Interleukin-6;Rheumatoid Arthritis; Juvenile Arthritis;Expert Testimony;Safety;Screening;tocilizumab;Administrative Personnel;Ligands;Population;Liver;Therapeutics;Infection
Publisher: BMJ Publishing Group
ISSN: 0003-4967
Date of First Compliant Deposit: 10 May 2018
Date of Acceptance: 21 October 2012
Last Modified: 10 May 2018 06:32
URI: http://orca.cf.ac.uk/id/eprint/110231

Citation Data

Cited 78 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics